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and the cervical collar. A dose volume histogram was 
generated and a dosimetric correlation of MRD with dose to 
2cc (D2cc), dose to 1cc (D1cc), maximum and mean rectal 
dose was calculated using spss software version 19. 
Results: The mean MRD was 3.11cm (range 2.32-3.77cm). 
D1cc, D2cc, mean rectal dose and maximum rectal doses 
were 3.51 Gy, 3.04 Gy, 1.63 Gy and 4.95 Gy per treatment, 
respectively. Statistical analysis revealed an increase in D2cc 
(p=0.02) and D1cc (p=0.05) with increasing rectal distension. 
Further it is possible to predict the increase in D2cc with 
increasing rectal distension using the linear regression model: 
'Increase in D2cc in cGy = 17.74 + 92.22 x Increase in rectal 
distension in cm'. 
 
Conclusions: D2cc increases significantly with increasing 
rectal distension in HDR brachytherapy for cervical cancer 
patients. Minimizing rectal distension by simple measures like 
overnight fasting, mild laxatives and enema are likely to 
minimize potential rectal toxicity. Hence efforts to decrease 
rectal distention during brachytherapy should be considered.  
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Purpose/Objective: Endometrial cancer is the commonest 
gynaecological malignancy with an increasing incidence. It is 
unclear whether patients with early stage endometrial cancer 
treated with surgery and no adjuvant therapy require regular 
gynaecological follow-up. 
Materials and Methods: Retrospective analysis of all cases of 
early stage endometrial cancer treated with surgery and no 
adjuvant therapy presenting with recurrence over a thirteen 
year time period in a single centre. Case notes and electronic 
records were reviewed to determine whether the recurrence 
presented symptomatically or was detected clinically on 
follow-up. The intent of treatment at recurrence was 
analysed to determine the 2-year survival for this patient 
group. 
Results: 35 patients were included, who presented with 
recurrence between 2000 and 2013. 10 patients (29%) were 
detected clinically on routine follow-up with 25 patients 
(71%) presenting symptomatically. 20 patients (57%) were 
treated with palliative intent (7 chemotherapy, 8 External 
Beam Radiotherapy (EBRT), 4 hormone treatments and 1 best 
supportive care) and 15 patients (43%) were treated with 
radical intent (9 EBRT followed by brachytherapy, 4 
brachytherapy alone and 2 receiving EBRT alone). Median 
follow-up was 22 months. Median survival overall was 23 
months, with palliative treatment was 10 months and with 
radical treatment was 53 months. 2-year survival following 
recurrence overall was 51.6%, following radical treatment 
was 78.5%, and following palliative treatment was 29.4%.  
Conclusions: With 71% of patients presenting with recurrence 
having symptoms, it would appear on the surface to be 
reasonable to alter the model of follow-up to be more 
patient-centred, with symptoms triggering referral rather 
than routine review. However, in view of 80% of patients 
whose recurrence is detected at Routine Follow-Up, going on 
to have radical treatment, it may be more appropriate to 
offer patients the choice of Routine Follow-Up or a telephone 
review/self-referral service. In times of pressure on NHS 
resources this may be a suitable way of managing this cohort 
of patients. 
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Purpose/Objective: The position of the vagina could be 
highly variable due to differences of bladder and rectal 
filling. In order to ensure adequate target coverage, RTOG 
first introduced ITV accounting for individualized organ 
motion affected by bladder filling. We investigate the 
magnitude of vaginal displacement along the treatment in 
patients treated with post-operative IMRT for gynaecological 
cancer. We evaluate the subsequent dosimetric coverage loss 
and look for any correlation with bladder and rectal filling. 
Materials and Methods: We retrospectively analyzed 27 
consecutive patients treated in our institution between July 
2012 and July 2014 with IMRT for post-operative treatment of 
gynaecological cancer.  
All patients underwent empty and full bladder CT simulation 
(CT planning). This procedure was repeated as a control 3 
weeks after (CT-control). Both sets of CTs were registered. 
The delineation of the volumes and the definition of ITV were 
performed following the RTOG guidelines in both CTs. 
ITV displacement was measured as the coordinates difference 
(in three axes) between the center-of-mass of both ITV, 
expressed in absolute value. With these values we calculated 
the 3D vector. 
The PTV was created by adding 0.7cm (margin) to ITV and 
CTV-node. Treatment planning was done on full bladder CT-
planning with IMRT. Plans were optimized and normalized to 
deliver 100% prescribed dose to 97% of PTV. 
These plans were recalculated (but not optimized) on the full 
bladder CT-control. 
